Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Freshworks Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.97 (market cap $4.59B), while Freshworks Inc trades at $13.81 (market cap $3.56B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Freshworks Inc for 39 Days on average.
| DFTX | FRSH | |
|---|---|---|
Market Cap | $4.59B | $3.56B |
Volume | 2,103,937 | 9,066,454 |
Sector | Health | Technology |
52-Week High | $48.45 | $13.92 |
52-Week Low | $10.68 | $6.88 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $3.55B | $2.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Freshworks (FRSH) trades at $13.60, down 1.16% on the day, with a bullish technical outlook from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with EPS of $0.17 versus $0.13 expected, and achieved its first quarter of GAAP profitability. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience portfolio and AI adoption.
The investment outlook is positive, driven by sustained revenue growth, improving profitability, and a favorable analyst consensus with a $14.60 price target. Key risks include high valuation multiples like a 43.89 EV/EBITDA and competitive pressures in the SaaS sector. The stock presents an opportunity for rerating if profitability trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
